KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Convertible Debt: 2010-2013

Historic Convertible Debt for Vertex Pharmaceuticals (VRTX) over the last 2 years, with Mar 2013 value amounting to $400.0 million.

  • Vertex Pharmaceuticals' Convertible Debt changed negligibly% to $400.0 million in Q1 2013 from the same period last year, while for Mar 2013 it was $400.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $400.0 million for FY2012, which is negligibly% changed negligibly from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Convertible Debt stood at $400.0 million for Q1 2013, which was down 0.00% from $400.0 million recorded in Q4 2012.
  • Over the past 5 years, Vertex Pharmaceuticals' Convertible Debt peaked at $400.0 million during Q3 2010, and registered a low of $400.0 million during Q3 2010.
  • Its 3-year average for Convertible Debt is $400.0 million, with a median of $400.0 million in 2013.